FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
This article was originally published in The Rose Sheet
Executive Summary
An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.
You may also be interested in...
As Demand for Functional Products Grows, Popular Actives Span Price Points
Consumers wanting “visible results” have increased demand for higher-end actives that were formerly predominantly exclusive to luxury products. Actives like vitamins, collagen and plant stem cells are now appearing in more affordable product formulations in hair care, sun care and anti-aging products.
Toxicity, Transparency & Sunscreen Regs Among Top “Rose Sheet” Topics In 2011
“The Rose Sheet” analyzes the stories that garnered the most reader interest and had the highest impact on the personal-care industry in 2011. The top topics include Johnson & Johnson’s reformulation of its baby-care products and the establishment of the Safe Cosmetics Alliance.
FDA Warning To Skin-Care Firm Shows Perils Of Cosmetics-To-Drug Transition
FDA's warning letter to skin-care product firm MW Laboratories for marketing unapproved new drugs illustrates the potentially perilous transition from marketing cosmeceuticals to making OTC claims